Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012;8(11):e1003001.
doi: 10.1371/journal.ppat.1003001. Epub 2012 Nov 8.

Vaccines: from empirical development to rational design

Christine Rueckert  1 , Carlos A Guzmán
Affiliations
Review

Vaccines: from empirical development to rational design

Christine Rueckert et al. PLoS Pathog. 2012.

Abstract

Infectious diseases are responsible for an overwhelming number of deaths worldwide and their clinical management is often hampered by the emergence of multi-drug-resistant strains. Therefore, prevention through vaccination currently represents the best course of action to combat them. However, immune escape and evasion by pathogens often render vaccine development difficult. Furthermore, most currently available vaccines were empirically designed. In this review, we discuss why rational design of vaccines is not only desirable but also necessary. We introduce recent developments towards specifically tailored antigens, adjuvants, and delivery systems, and discuss the methodological gaps and lack of knowledge still hampering true rational vaccine design. Finally, we address the potential and limitations of different strategies and technologies for advancing vaccine development.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Optimizing the design for more efficient vaccines.
Modern vaccinology focuses on the development of subunit vaccines to maximize efficacy and minimize risks in healthy and immune-compromised individuals. Different enabling technologies and knowledge contribute towards the rational design of formulations that would not only exhibit improved performance but also reduce the time and costs associated with preclinical and clinical development. Promising approaches/enabling factors and roadblocks are highlighted in green and pink, respectively.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Theiler M, Smith HH (1937) The use of yellow fever virus modified by in vitro cultivation for human immunization. J Exp Med 65: 787–800. - PMC - PubMed
    1. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K (1981) Persistence of neutralizing antibody 30–35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 59: 895–900. - PMC - PubMed
    1. Sette A, Rappuoli R (2010) Reverse vaccinology: developing vaccines in the era of genomics. Immunity 33: 530–541. - PMC - PubMed
    1. Bagnoli F, Baudner B, Mishra RP, Bartolini E, Fiaschi L, et al. (2011) Designing the next generation of vaccines for global public health. OMICS 15: 545–566. - PubMed
    1. Poland GA, Kennedy RB, Ovsyannikova IG (2011) Vaccinomics and personalized vaccinology: is science leading us toward a new path of directed vaccine development and discovery? PLoS Pathog 7: e1002344 doi:10.1371/journal.ppat.1002344 - DOI - PMC - PubMed

Publication types

Grants and funding

This work was supported in part by grants from the EU (PANFLUVAC, TRANSVAC); BMBF in the context of the programs Gerontosys 2 (Gerontoshield), EuroNanoMed (HCVAX) and ERANetRUS (HCRUS), and the Helmholtz Association (IG-SCID). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.